This study Identifies the possible risk factors for osteonecrosis (ON) in a homogenous group of early system lupus erythematosus (SLE). Forty-six consecutive SLE patients (<5 years duration) followed at the Lupus Clinic, were enrolled between 2004 and 2005. An extensive clinical and laboratory evaluation using a standard electronic protocol established since 1999, including osteonecrosis symptoms and appropriate magnetic resonance imaging (MRI), were carried out at 1—6 months intervals. All other asymptomatic for osteonecrosis patients at study entry underwent MRI. ON confirmed by MRI was found in 10 of 46 patients (22%). Age, disease duration, clinical vascular features, frequency of thrombophilia and hypofibrinolysis factors and the lipoprotein profile were comparable in patients with and without osteonecrosis (P > 0.05). Remarkably, the frequency of patients with system lupus erythematosus disease activity index (SLEDAI) ≥8 in the previous year of osteonecrosis clinical diagnosis was significantly higher when compared to patients without this manifestation (60.0% versus 19.4%, P = 0.011), supported by the higher glucocorticoid cumulative dose in the same period (P = 0.045). In contrast, these two parameters evaluated in 13th—24th months preceding osteonecrosis diagnosis were similar in patients with and without osteonecrosis (P > 0.05). In the logistic regression analysis only SLEDAI remained as an independent risk factor for ON (OR = 6.78, CI = 1.05—43.55, P = 0.04). Disease activity in the previous year of ON clinical diagnosis is the main predictor factor for the development of this complication in early SLE. Lupus (2007) 16, 239—244.
Mont MA, Carbone JJ, Fairbank ACCore decompression versus non-operative management for osteonecrosis of the hip. Clin Orthop Relat Res1996; 324: 169—178.
2.
Ficat RPIdiopathic bone necrosis of the femoral head. J Bone Joint Surg1985; 67B: 3—9.
3.
Dubois EL, Cozen L.Avascular (aseptic) bone necrosis associated with systemic lupus erythematosus . JAMA1960; 174: 966—971.
4.
Zizic TM, Marcoux C., Hungerford DS, Dansereau JV, Stevens MBCorticosteroid therapy associated with ischemic necrosis of bone in systemic lupus erythematosus. Am J Med1985 ; 79: 596—604.
5.
Weiner ES, Abeles M.Aseptic necrosis and glucocorticosteroids in systemic lupus erythematosus: a reevaluation. J Rheumatol1989; 16: 604—608.
6.
Massardo L., Jacobelli S., Leissner M., Gonzalez M., Villarroel L., Rivero S.High-dose intravenous methylprednisolone therapy associated with osteonecrosis in patients with systemic lupus erythematosus. Lupus1992; 1: 401—405.
7.
Migliaresi S. , Picillo U., Ambrosone L. et al. Avascular osteonecrosis in patients with SLE: relation to corticosteroid therapy and anticardiolipin antibodies . Lupus1994; 3: 37—41.
8.
Mont MA, Glueck CJ, Pacheco IH, Wang P., Hungerford DS, Petri M.Risk factors for osteonecrosis in systemic lupus erythematosus. J Rheumatol1997; 24: 654—662.
9.
Mok CC, Lau CS, Wong RWRisk factors for avascular bone necrosis in systemic lupus erythematosus. Br J Rheumatol1998; 37: 895—900.
10.
Zizic TM, Hungerford DS, Stevens MBIschemic bone necrosis in systemic lupus erythematosus. The early diagnosis of ischemic necrosis of bone. Medicine1980 ; 59: 134—142.
11.
Abeles M., Urman JD, Rothfield NFAseptic necrosis of bone in systemic lupus erythematosus. Relationship to corticosteroid therapy. Arch Inter Med1978 ; 138: 750—754.
12.
Sheik JS, Retzinger GS, Hess EVAssociation of osteonecrosis in systemic lupus erythematosus with abnormalities of fibrinolysis. Lupus1998; 7: 42—48.
13.
Rascu A., Manger K., Kraetsch HG, Kalden JR, Manger B.Osteonecrosis in systemic lupus erythematosus, steroid-induced or a lupus-dependent manifestation?Lupus1996 ; 5: 323—327.
14.
Klippel JH, Gerberg LH, Pollak L., Decker JLAvascular necrosis of bone in systemic lupus erythematosus: silent symmetric osteonecrosis. Am J Med1979; 67: 83—87.
15.
Zizic TMAvascular necrosis of bone. Curr Opin Rheumatol1990; 2: 26—37.
16.
Bergstein JM , Wiens C., Fish AJ, Vernier RL, Michael A.Avascular necrosis of bone in systemic lupus erythematosus. J Pediatr1974; 85: 31—35.
17.
Nagasawa K., Tsukamoto H., Tada Y. et al. Imaging study on the mode of development and changes in avascular necrosis of the femoral head in systemic lupus erythematosus: long term observations . Br J Rheumatol1994; 33: 343—347.
18.
Aranow C., Zelicof S., Leslie D. et al. Clinically occult avascular necrosis of the hip in systemic lupus erythematosus. J Rheumatol1997; 24: 2318—2322.
19.
Oinuma K., Harada Y., Nawata Y. et al. Osteonecrosis in patients with systemic lupus erythematosus develops very early after starting high dose corticosteroid treatment. Ann Rheum Dis2001; 60: 1145—1148.
20.
Gladman DD, Urowitz MB, Chaudry-Ahluwalia V., Hallet DC, Cook RJPredictive factors for symptomatic osteonecrosis in patients with systemic lupus erythematosus. J Rheumatol2001; 28: 761—765.
21.
Nagasawa K. , Ishii YI, Mayumi T. et al. Avascular necrosis of bone in systemic lupus erythematosus: possible role of haemostatic abnormalities . Ann Rheum Dis1989; 48: 672—676.
22.
Houssiau FA , Toukap NA, Depresseux G. et al. Magnetic resonance-imaging-detected avascular osteonecrosis in systemic lupus erythematosus: lack of correlation with antiphospholipid antibodies. Br J Rheumatol1998; 37: 448—453.
23.
Nagasawa K. , Tada Y., Koarada S. et al. Very early development of steroid-associated osteonecrosis of femoral head in systemic lupus erythematosus: prospective study by MRI. Lupus2005; 14: 385—390.
24.
Nilsen KHSystemic lupus erythematosus and avascular bone necrosis. N Z Med J1977; 8: 472—475.
25.
Hungerford DS, Zizic TMThe treatment of ischemic necrosis of bone in systemic lupus erythematosus. Medicine1980; 59: 143—148.
26.
Abeles M., Weiner ES, Parke A., Wilson D.The association of osteonecrosis in SLE with anticardiolipin antibodies . Arthritis Rheum1991; 34(Suppl): R39.
27.
Asherson RA , Liote F., Page B. et al. Avascular necrosis of bone and antiphospholipid antibodies in systemic lupus erythematosus. J Rheumatol1993; 20: 284—288.
Tektonidou MG, Malagari K., Vlachoyiannopoulos PG, Kelekis DA, Moutsopoulos HMAsymptomatic avascular necrosis in patients with primary antiphospholipid syndrome in the absence of corticosteroid use: a prospective study by resonance imaging. Arthritis Rheum2003; 48: 732—736.
30.
Jones LC, Mont MA, Le TB et al. Progoagulants and Osteonecrosis. J Rheumatol2003; 30: 783—791.
31.
Ibanez D., Gladman DD, Urowitz MBAdjusted mean Systemic Lupus Erythematosus Disease Activity Index-2K is a predictor of outcome in SLE. J Rheumatol2005 ; 32: 824—827.
32.
Mok MY, Farewell VT, Isenberg DARisk factors for avascular necrosis of bone in patients with systemic lupus erythematosus: is there a role for antiphospholipid antibodies?Ann Rheum Dis2000; 59: 462—467.
33.
Halland AM, Klemp P., Botes D., Van Heerden BB, Loxton A., Scher ATAvascular necrosis of the hip in systemic lupus erythematosus: the role of magnetic resonance imaging. Br J Rheumatol1993; 32: 972—976.
34.
Kalunian KC , Hahn BH, Bassett L.Magnetic resonance imaging identifies early femoral head ischemic necrosis in patients receiving systemic glucocorticoid therapy. J Rheumatol1989; 16: 959—963.
35.
Mitchell DG , Rao VM, Dalinka MK et al. Femoral head avascular necrosis: correlation of MR imaging, radiographic staging, radionuclide imaging, and clinical findings . Radiology1987; 162: 709—715.
36.
Markisz JA, Knowles RJ, Altchek DW, Schneider R., Whalen J., Cahill PTSegmenal patterns of avascular necrosis of the femoral heads: early detection with MR imaging. Radiology1987; 162: 717—720.
37.
Hochberg MCUpdating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum1997; 40: 1725 (letter).
38.
Bombardier C., Gladman DD, Urowitz MB, Caron D., Chang CH, and the Committee on Prognosis Studies in SLE.Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum1992; 35: 630—640.
39.
Gladman D., Ginzler E., Goldsmith C. et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum1996; 39: 363—369.
40.
Talamo G., Angtuaco E., Walker RC et al. Avascular necrosis of femoral and/or humeral heads in multiple myeloma: results of a prospective study of patients treated with dexamethasone-based regimes and high-dose chemotherapy. J Clin Oncol2005; 23: 5217—5223.
41.
Schulte CM, Beelen DWAvascular osteonecrosis after allogenic hematopoietic stem-cell transplantation: diagnosis and gender matter. Transplantation2004; 78: 1055—1063.
42.
Bjorkman A. , Burtscher IM, Svensson PJ, Hillarp A., Besjakov J., Benoni G.Factor V Leiden and prothrombin 20210A gene mutation and osteonecrosis of the knee. Arch Orthop Trauma Surg2005; 125: 51—55.
43.
Bjorkman A. , Svensson PJ, Hillarp A., Burtscher IM, Runow A., Benoni G.Factor V Leiden and prothrombin gene mutation: risk factors for osteonecrosis of femoral head in adults. Clin Orthop Relat Res2004; 425: 168—172.
44.
Sakamoto M. , Shimizu K., Lida S., Akita T., Moriya H., Nawata Y.Osteonecrosis of the femoral head: a prospective study with MRI. J Bone Joint Surg Br1997; 79: 213—219.
45.
Colwell Cw Jr, Robinson CA, Stevenson DD, Vint VC, Morris BAOsteonecrosis of the femoral head in patients with inflammatory arthritis or asthma receiving corticosteroid therapy. Orthopedics1996; 19: 941—946.
